Nutrient biomarkers and vascular risk factors in subtypes of mild cognitive impairment: A cross-sectional study

Journal of Nutrition, Health and Aging

Volumn 19, Issue 1, 2015, Pages 39-47

  Yin, Y ^a   Fan, Y ^a   Lin, F ^b   Xu, Y ^a   Zhang, Junjian ^a  

^a WUHAN UNIVERSITY   (China)

^b JIANGHAN UNIVERSITY   (China)

Author keywords

framingham stroke risk profile; mild cognitive impairment; Nutrient biomarkers; vascular risk factors

Indexed keywords

25 HYDROXYVITAMIN D; DOCOSAHEXAENOIC ACID; FOLIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; VITAMIN D;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FATTY ACID BLOOD LEVEL; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; NUTRIENT; PRIORITY JOURNAL; RISK ASSESSMENT; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CEREBROVASCULAR ACCIDENT; CLASSIFICATION; COMPLICATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUTRITIONAL STATUS; PHYSIOLOGY; PSYCHOLOGY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CROSS-SECTIONAL STUDIES; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; EXECUTIVE FUNCTION; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; NUTRITIONAL STATUS; RISK FACTORS; STROKE; VITAMIN D;

EID: 84922005518     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-014-0510-8     Document Type: Article

References (60)

1. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B. Mild cognitive impairment. Lancet 2006;367:1262–1270
2. Huang J, Meyer JS, Zhang Z, Wei J, Hong X, Wang J, Wen H, Wu W, Wu J, Chowdhury MH. Progression of mild cognitive impairment to Alzheimer’s or vascular dementia versus normative aging among elderly Chinese. Curr Alzheimer Res 2005;2:571–578
3. Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O. Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. PLoS One 2012;7:e38639
4. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MMB. Progression of Cerebral Small Vessel Disease in Relation to Risk Factors and Cognitive Consequences Rotterdam Scan Study. Stroke 2008;39:2712–2719
5. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Archives of general psychiatry 2006;63:273
6. Elias MF, Sullivan LM, D’Agostino RB, Elias PK, Beiser A, Au R, Seshadri S, DeCarli C, Wolf PA. Framingham stroke risk profile and lowered cognitive performance. Stroke 2004;35:404–409
7. Kaffashian S, Dugravot A, Brunner EJ, Sabia S, Ankri J, Kivimaki M, Singh-Manoux A. Midlife stroke risk and cognitive decline: a 10-year follow-up of the Whitehall II cohort study. Alzheimers Dement 2013;9:572–579
8. Llewellyn DJ, Lang IA, Xie J, Huppert FA, Melzer D, Langa KM. Framingham Stroke Risk Profile and poor cognitive function: a population-based study. BMC Neurol 2008;8:12
9. Nishtala A, Preis SR, Beiser A, Devine S, Hankee L, Seshadri S, Wolf PA, Au R. Midlife Cardiovascular Risk Impacts Executive Function: Framingham Offspring Study. Alzheimer Dis Assoc Disord, 2013
10. D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994;25:40–43
11. Unverzagt FW, McClure LA, Wadley VG, Jenny NS, Go RC, Cushman M, Kissela BM, Kelley BJ, Kennedy R, Moy CS, Howard V, Howard G. Vascular risk factors and cognitive impairment in a stroke-free cohort. Neurology 2011;77:1729–1736
12. Brady CB, Spiro A, McGlinchey-Berroth R, Milberg W, Gaziano JM. Stroke risk predicts verbal fluency decline in healthy older men: evidence from the normative aging study. J Gerontol B Psychol Sci Soc Sci 2001;56:P340–346
13. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011;42:2672–2713
14. Singh B, Parsaik AK, Mielke MM, Erwin PJ, Knopman DS, Petersen RC, Roberts RO. Association of Mediterranean Diet with Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer’s Disease, 2014
15. Bayer-Carter JL, Green PS, Montine TJ, VanFossen B, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Walter BK, Tsai E, Plymate SR, Postupna N, Wilkinson CW, Zhang J, Lampe J, Kahn SE, Craft S. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol 2011;68:743–752
16. Rondanelli M, Opizzi A, Faliva M, Mozzoni M, Antoniello N, Cazzola R, Savare R, Cerutti R, Grossi E, Cestaro B. Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment. Nutr Neurosci 2012;15:46–54
17. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Tettamanti M, Lucca U. Homocysteine and B vitamins in mild cognitive impairment and dementia. Clin Chem Lab Med 2005;43:1096–1100
18. Annweiler C, Fantino B, Schott AM, Krolak-Salmon P, Allali G, Beauchet O. Vitamin D insufficiency and mild cognitive impairment: cross-sectional association. Eur J Neurol 2012;19:1023–1029
19. Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA, Morris MC. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2012;29:691–697
20. Lee LK, Shahar S, Rajab N, Yusoff NA, Jamal RA, Then SM. The role of long chain omega-3 polyunsaturated fatty acids in reducing lipid peroxidation among elderly patients with mild cognitive impairment: a case-control study. J Nutr Biochem 2013;24:803–808
21. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research 1975;12:189–198
22. Nasreddine ZS, Phillips NA, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 2005;53:695–699
23. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 1993
24. Perneczky R, Pohl C, Sorg C, Hartmann J, Komossa K, Alexopoulos P, Wagenpfeil S, Kurz A. Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. Age and ageing 2006;35:240–245
25. Gilewski MJ, Zelinski EM. Memory Functioning Questionnaire (MFQ). Psychopharmacology bulletin 1988;24:665–670
26. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. The American journal of psychiatry, 1984
27. Xu ZY, Wang X, Si YY, Wu JC, Zuo YX, Xue FS, Liu J. Intravenous remifentanil and propofol for gastroscopy. Journal of clinical anesthesia 2008;20:352–355
28. Lu L, Bigler ED. Normative data on trail making test for neurologically normal, Chinese-speaking adults. Applied Neuropsychology 2002;9:219–225
29. Bryan J, Luszcz MA, Crawford JR. Verbal knowledge and speed of information processing as mediators of age differences in verbal fluency performance among older adults. Psychology and aging 1997;12:7
30. Lu J, Li D, Li F, Zhou A, Wang F, Zuo X, Jia X-F, Song H, Jia J. Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. Journal of geriatric psychiatry and neurology 2011;24:184–190
31. Zheng YP, Zhao JP, Phillips M, Liu JB, Cai MF, Sun SQ, Huang MF. Validity and reliability of the Chinese Hamilton Depression Rating Scale. The British Journal of Psychiatry 1988;152:660–664
32. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–246
33. Zhao Q, Xiong Y, Ding D, Guo Q, Hong Z. Synergistic Effect between apolipoprotein E e4 and Diabetes Mellitus for Dementia: Result from a Population-Based Study in Urban China. Journal of Alzheimer’s Disease 2012;32:1019–1027
34. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497–509
35. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992
36. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC. Subclassifications for mild cognitive impairment: prevalence and predictive validity. Psychol Med 2003;33:1029–1038
37. Rasquin SM, Lodder J, Visser PJ, Lousberg R, Verhey FR. Predictive accuracy of MCI subtypes for Alzheimer’s disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study. Dement Geriatr Cogn Disord 2005;19:113–119
38. Alexopoulos P, Grimmer T, Perneczky R, Domes G, Kurz A. Progression to dementia in clinical subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2006;22:27–34
39. Lee HK, Lee YM, Park JM, Lee BD, Moon ES, Chung YI. Amnestic multiple cognitive domains impairment and periventricular white matter hyperintensities are independently predictive factors progression to dementia in mild cognitive impairment. Int J Geriatr Psychiatry, 2013
40. Eskelinen MH, Ngandu T, Helkala EL, Tuomilehto J, Nissinen A, Soininen H, Kivipelto M. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry 2008;23:741–747
41. Solfrizzi V, Colacicco AM, D’Introno A, Capurso C, Del Parigi A, Capurso SA, Argentieri G, Capurso A, Panza F. Dietary fatty acids intakes and rate of mild cognitive impairment. The Italian Longitudinal Study on Aging. Exp Gerontol 2006;41:619–627
42. Milte CM, Sinn N, Street SJ, Buckley JD, Coates AM, Howe PR. Erythrocyte polyunsaturated fatty acid status, memory, cognition and mood in older adults with mild cognitive impairment and healthy controls. Prostaglandins Leukot Essent Fatty Acids 2011;84:153–161
43. Roberts RO, Cerhan JR, Geda YE, Knopman DS, Cha RH, Christianson TJ, Pankratz VS, Ivnik RJ, O’Connor HM, Petersen RC. Polyunsaturated fatty acids and reduced odds of MCI: the Mayo Clinic Study of Aging. J Alzheimers Dis 2010;21:853–865
44. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY. The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1538–1544
45. Lee LK, Shahar S, Chin AV, Yusoff NA. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2013;225:605–612
46. Sinn N, Milte CM, Street SJ, Buckley JD, Coates AM, Petkov J, Howe PR. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 2012;107:1682–1693
47. Dacks PA, Shineman DW, Fillit HM. Current evidence for the clinical use of longchain polyunsaturated N-3 fatty acids to prevent age-related cognitive decline and Alzheimer’s disease. The journal of nutrition, health & aging 2013;17:240–251
48. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 2009;5:140–152
49. Abeywardena MY, Patten GS. Role of omega3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors. Endocr Metab Immune Disord Drug Targets 2011;11:232–246
50. Buell JS, Dawson-Hughes B, Scott TM, Weiner DE, Dallal GE, Qui WQ, Bergethon P, Rosenberg IH, Folstein MF, Patz S, Bhadelia RA, Tucker KL. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010;74:18–26
51. Wang JY, Wu JN, Cherng TL, Hoffer BJ, Chen HH, Borlongan CV, Wang Y. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res 2001;904:67–75
52. Ibi M, Sawada H, Nakanishi M, Kume T, Katsuki H, Kaneko S, Shimohama S, Akaike A. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 2001;40:761–771
53. Wang Y, Chiang YH, Su TP, Hayashi T, Morales M, Hoffer BJ, Lin SZ. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000;39:873–880
54. Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, Zheng X, Espinosa-Jeffrey A, Mahanian M, Liu PT, Hewison M, Mizwickie M, Cashman J, Fiala M. 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 2009;17:703–717
55. Dickens AP, Lang IA, Langa KM, Kos K, Llewellyn DJ. Vitamin D, cognitive dysfunction and dementia in older adults. CNS Drugs 2011;25:629–639
56. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010;5:e12244
57. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 2011;27:592–600
58. van Uffelen JG, Chin APMJ, Hopman-Rock M, van Mechelen W. The effect of walking and vitamin B supplementation on quality of life in community-dwelling adults with mild cognitive impairment: a randomized, controlled trial. Qual Life Res 2007;16:1137–1146
59. Ford AH, Almeida OP. Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials. J Alzheimers Dis 2012;29:133–149
60. Annweiler C, Le Gall D, Fantino B, Beauchet O, Tucker KL, Buell JS. 25- hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010;75:95; author reply 95-96